991-P: High Treatment Satisfaction with 3-Day Insulin Patch Is Independent of Patient Demographics

Abstract

This post-hoc analysis explores whether high treatment satisfaction seen with a 3-day wearable patch for mealtime insulin subcutaneous delivery is applicable across different patient groups. The randomized multi-country study of adults (n=278, age: 59.2±8.9 years) with type 2 diabetes transitioned patients from basal-only to basal plus mealtime insulin therapy using one of two methods of mealtime insulin delivery. Patients were randomized 1:1 to deliver mealtime insulin using either a 3-day insulin patch or an insulin pen. Published data demonstrated that basal plus mealtime insulin therapy using either device similarly reduced A1C (1.7% patch, 1.6% pen). However, patients were more satisfied with patch than pen (Overall Satisfaction, Insulin Delivery System Rating Questionnaire (IDSRQ) p<0.01). In this abstract, comparison of IDSRQ satisfaction was analyzed by age, sex and BMI. There were no significant (p<0.05) interactions between baseline patient demographics and device. None of the subgroups favored pen over patch. Notably, patients above 65 years preferred the patch similarly to those below 65 years of age; resistance to new technology was not seen. Patch was similarly preferred by those of all body masses and both genders. In summary, the data indicate that the 3-day insulin patch is suitable for patients independent of demographics, and preferred to pen overall. Disclosure M. Peyrot: Advisory Panel; Self; Eli Lilly and Company. Consultant; Self; CeQur Corporation, Eli Lilly and Company. Research Support; Spouse/Partner; Eli Lilly and Company. D. Johns: None. B.R. Rees: Employee; Self; CeQur Corporation. R. Rook: Consultant; Self; CeQur Corporation. J.L. Warner: Employee; Self; CeQur Corporation. B.L. Levy: Consultant; Self; CeQur Corporation, Digma Medical, iGlucose, LifeScan, Inc., QuiO Technologies.